MLTX (STOCKS)
MoonLake Immunotherapeutics Class A Ordinary Shares
$18.470000
+0.510000 (+2.84%)
Prev close: $17.960000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Jorge Santos da Silva
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $1,320.51M
- Employees
- 100
- P/E (TTM)
- -5.23
- P/B (TTM)
- 4.21
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
8
Strong Buy
10
Buy
3
Hold
1
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Dec 2025 (Q4)
|
$-0.92 | $-1.01 | +0.0911 | +9.03% |
|
Sep 2025 (Q3)
|
$-1.10 | $-0.90 | -0.2039 | -22.75% |
|
Jun 2025 (Q2)
|
$-0.87 | $-0.74 | -0.1343 | -18.25% |
|
Mar 2025 (Q1)
|
$-0.63 | $-0.77 | +0.1373 | +17.89% |
Financial Statements
| Revenues | $0.00 |
| Operating Expenses | $244.83M |
| Research and Development | $202.86M |
| Other Operating Expenses | $41.97M |
| Operating Income/Loss | -$244.83M |
| Income/Loss From Continuing Operations After Tax | -$230.32M |
| Income/Loss From Continuing Operations Before Tax | -$229.71M |
| Income Tax Expense/Benefit | $611.00K |
| Net Income/Loss | -$230.32M |
| Net Income/Loss Attributable To Noncontrolling Interest | -$3.00M |
| Net Income/Loss Attributable To Parent | -$227.32M |
| Net Income/Loss Available To Common Stockholders, Basic | -$227.32M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$3.53 |
| Diluted Earnings Per Share | -$3.53 |
| Basic Average Shares | 64,463,889 |
| Diluted Average Shares | 64,463,889 |
| Assets | $424.43M |
| Current Assets | $421.69M |
| Prepaid Expenses | $22.86M |
| Other Current Assets | $398.84M |
| Noncurrent Assets | $2.74M |
| Fixed Assets | $577.00K |
| Other Non-current Assets | $2.16M |
| Liabilities | $119.95M |
| Current Liabilities | $45.48M |
| Wages | $2.32M |
| Other Current Liabilities | $43.15M |
| Noncurrent Liabilities | $74.47M |
| Long-term Debt | $74.10M |
| Other Non-current Liabilities | $374.00K |
| Equity | $304.48M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $304.48M |
| Liabilities And Equity | $424.43M |
| Net Cash Flow From Operating Activities | -$196.01M |
| Net Cash Flow From Operating Activities, Continuing | -$196.01M |
| Net Cash Flow From Investing Activities | $202.99M |
| Net Cash Flow From Investing Activities, Continuing | $202.99M |
| Net Cash Flow From Financing Activities | $146.00M |
| Net Cash Flow From Financing Activities, Continuing | $146.00M |
| Net Cash Flow | $152.98M |
| Net Cash Flow, Continuing | $152.98M |
| Comprehensive Income/Loss | -$234.80M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | -$3.07M |
| Comprehensive Income/Loss Attributable To Parent | -$231.73M |
| Other Comprehensive Income/Loss | -$4.48M |